Decibel Therapeutics. has filed a patent for cell lines that express a CRISPR SAM complex targeting specific genes not typically expressed in the cell. The patent also covers methods to measure vector efficiency in transferring nucleic acid molecules into these cell lines. GlobalData’s report on Decibel Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Decibel Therapeutics Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Decibel Therapeutics, Recombinant AAV gene therapy was a key innovation area identified from patents. Decibel Therapeutics's grant share as of January 2024 was 8%. Grant share is based on the ratio of number of grants to total number of patents.

Cell lines expressing crispr sam complex for gene activation

Source: United States Patent and Trademark Office (USPTO). Credit: Decibel Therapeutics Inc

A recent patent application (Publication Number: US20240002839A1) discloses a cell engineered to stably express a CRISPR/Cas9 Synergistic Activation Mediator complex (CRISPR SAM complex). This complex includes a guide RNA (gRNA) that targets a specific gene promoter, resulting in the activation of a gene that is not typically expressed in the cell. The CRISPR SAM complex contains a modified Cas9 protein with reduced or eliminated nuclease activity, fused to transcriptional activation domains. The gRNA used in the cell can be an sgRNA with specific RNA aptamers, and the cell itself is specified to be a mammalian cell, including human cells like HEK293 cells.

Furthermore, the patent application includes claims related to specific gRNA sequences targeting the Myo15 promoter, as well as the creation of an HEK231 cell line expressing the CRISPR SAM complex. Additionally, methods for assessing the efficiency of gene transfer vectors into cells are described, involving the introduction of nucleic acid molecules encoding genes linked to specific promoters targeted by gRNAs. Various vectors such as viruses (AAV, retrovirus, lentivirus, adenovirus), lipid nanoparticles, and reporter genes like EGFP are mentioned in the claims. The patent application also covers the introduction of genes by multiple vectors for enhanced gene expression in cells, showcasing the versatility and potential applications of the disclosed technology.

To know more about GlobalData’s detailed insights on Decibel Therapeutics, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies